APP announces clearance

Schaumburg-based APP Pharmaceuticals Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding Inc. announced that it has received clearance from the U.S. Food and Drug Administration to market preservative-free Heparin Lock Flush Solution, USP in two dosage strengths, 10 USP Units/1 mL and 100 USP Units/1 mL, and will soon launch these single dose vial presentations.

APP is a consistent supplier of heparin to the marketplace and this approval provides health care professionals with the only preservative-free Heparin Lock Flush Solution in a single dose vial.

Benzyl alcohol has been associated with toxicity in neonates and has been reported to be associated with a fetal "Gasping Syndrome" in premature infants.